High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Trial Profile

High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Dexamethasone; Filgrastim; Palifermin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 02 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top